ArticleHistology and histopathology2026
Naoluotong granules inhibit necroptosis of neural cells and improve cerebral ischemia-reperfusion injury by regulating the RIP1/NIK/IKKα/NF-κB pathway.
Article in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCerebral ischemia-reperfusion can cause structural changes in brain tissue and disrupt physiological functions. Naoluotong granules (NLT) exhibit significant neuroprotective effects on brain nerve cells and are widely utilized in treating cerebral ischemia-reperfusion injury (CIRI). However, the underlying molecular mechanisms remain elusive.
methodsThe CIRI model was established
resultsNecroptosis plays a significant role in the onset and progression of ischemia-reperfusion-induced neural injury.
conclusionsThis study confirms that the significant neuroprotective effects of NLT and AST-IV in alleviating CIRI are related to inhibiting necrosis by suppressing the RIP1/NIK/IKKα/NF-κB pathway.
Indexed as
Identifiers
41556105What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.